SUNNYVALE, Calif., Sept. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based biotechnology company developing new treatments and diagnostics for Parkinson's disease (PD) and Traumatic Brain Injury (TBI) centered around its patented therapeutic protein MANF, today announced that Co-Founders Dr. John and Gerald Commissiong were selected among BlackMoney.com's 13 th annual "50 Most Important African-Americans in Technology" for 2012. The selectees will gather in Washington, D.C. January 15 th, 2013 for the Innovation & Equity Symposium: Keeping America First in Technology: Public Innovation and Supplier Diversity ( http://www.blackmoney.com/35117 ).
Dr. John W. Commissiong, Amarantus' Chief Scientific Officer, is the former Head of the Neurotrophic Factors Group at the National Institute of Neurological Disorders and Stroke (NINDS) who discovered and patented MANF. Gerald E. Commissiong, the Company's President & CEO, graduated from Stanford University's Management Science and Engineering program with a focus in Financial Decisions. Their bios can be viewed online at: http://www.amarantus.com/about-us/management-team.html .
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to diagnose and treat Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.